Wendy Fang

689 total citations
17 papers, 563 citations indexed

About

Wendy Fang is a scholar working on Molecular Biology, Neurology and Cancer Research. According to data from OpenAlex, Wendy Fang has authored 17 papers receiving a total of 563 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 6 papers in Neurology and 6 papers in Cancer Research. Recurrent topics in Wendy Fang's work include Cancer, Hypoxia, and Metabolism (6 papers), Neuroblastoma Research and Treatments (6 papers) and Histone Deacetylase Inhibitors Research (3 papers). Wendy Fang is often cited by papers focused on Cancer, Hypoxia, and Metabolism (6 papers), Neuroblastoma Research and Treatments (6 papers) and Histone Deacetylase Inhibitors Research (3 papers). Wendy Fang collaborates with scholars based in United States, New Zealand and Australia. Wendy Fang's co-authors include Patrick A. Zweidler‐McKay, Sankaranarayanan Kannan, Riitta Nolo, Peter E. Zage, Sandra M. Swain, Marc E. Lippman, Joachim Sasse, Aparajita Khatri, Anton Wellstein and Robert B. Dickson and has published in prestigious journals such as Journal of Biological Chemistry, The Journal of Experimental Medicine and The EMBO Journal.

In The Last Decade

Wendy Fang

15 papers receiving 557 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wendy Fang United States	9	383	165	124	100	91	17	563
Hashmat Sikder United States	6	366 1.0×	125 0.8×	30 0.2×	135 1.4×	51 0.6×	6	515
R. Habets Netherlands	8	357 0.9×	161 1.0×	24 0.2×	178 1.8×	32 0.4×	8	535
Chengyu Prince United States	11	333 0.9×	55 0.3×	62 0.5×	78 0.8×	18 0.2×	20	540
Maria Grazia Cipolleschi Italy	14	178 0.5×	121 0.7×	135 1.1×	72 0.7×	33 0.4×	21	436
Takuma Shikata Japan	8	457 1.2×	85 0.5×	40 0.3×	154 1.5×	34 0.4×	10	620
Ghada Abboud-Jarrous Israel	11	486 1.3×	98 0.6×	86 0.7×	78 0.8×	468 5.1×	13	756
Anna Chorzalska United States	12	230 0.6×	42 0.3×	52 0.4×	58 0.6×	78 0.9×	40	410
Donia M. Moujalled Australia	9	538 1.4×	81 0.5×	127 1.0×	73 0.7×	26 0.3×	17	689
Arindam Chaudhury United States	6	659 1.7×	184 1.1×	17 0.1×	197 2.0×	104 1.1×	6	847
Hiroshi Shin Japan	8	197 0.5×	117 0.7×	125 1.0×	54 0.5×	160 1.8×	9	516

Countries citing papers authored by Wendy Fang

Since Specialization

Citations

This map shows the geographic impact of Wendy Fang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wendy Fang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wendy Fang more than expected).

Fields of papers citing papers by Wendy Fang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wendy Fang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wendy Fang. The network helps show where Wendy Fang may publish in the future.

Co-authorship network of co-authors of Wendy Fang

This figure shows the co-authorship network connecting the top 25 collaborators of Wendy Fang. A scholar is included among the top collaborators of Wendy Fang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wendy Fang. Wendy Fang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Zhang, Xiyuan, Carly M. Sayers, Wendy Fang, et al.. (2025). MYCN and KAT2A form a feedforward loop to drive an oncogenic transcriptional program in neuroblastoma. Oncogenesis. 14(1). 13–13.

Xu, Man, Xiyuan Zhang, Ming Sun, et al.. (2024). Targeting SWI/SNF ATPases reduces neuroblastoma cell plasticity. The EMBO Journal. 43(20). 4522–4541. 3 indexed citations

Speed, Brittany C., Kathleen Sherman, Michael Shaw, et al.. (2015). Assessing cognition in MS clinical trials: The Cognitive Assessment Interview (CAI) (P3.233). Neurology. 84(14_supplement). 1 indexed citations

Kannan, Sankaranarayanan, Robert M. Sutphin, Leonard S. Golfman, et al.. (2013). Notch activation inhibits AML growth and survival: a potential therapeutic approach. The Journal of Experimental Medicine. 210(2). 321–337. 122 indexed citations

Zage, Peter E., Riitta Nolo, Wendy Fang, et al.. (2011). Notch pathway activation induces neuroblastoma tumor cell growth arrest. Pediatric Blood & Cancer. 58(5). 682–689. 41 indexed citations

Fang, Wendy, et al.. (2011). Targeting glycolysis in leukemia: A novel inhibitor 3-BrOP in combination with rapamycin. Leukemia Research. 35(6). 814–820. 44 indexed citations

Benito, Juliana, Yuexi Shi, Barbara Szymanska, et al.. (2011). Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104. PLoS ONE. 6(8). e23108–e23108. 98 indexed citations

Kannan, Sankaranarayanan, Wendy Fang, Guangchun Song, et al.. (2011). Notch/HES1-mediated PARP1 activation: a cell type–specific mechanism for tumor suppression. Blood. 117(10). 2891–2900. 48 indexed citations

Zage, Peter E., Wendy Fang, Christine Pien, et al.. (2010). The selective Trk inhibitor AZ623 inhibits brain‐derived neurotrophic factor–mediated neuroblastoma cell proliferation and signaling and is synergistic with topotecan. Cancer. 117(6). 1321–1391. 24 indexed citations

10.

Zage, Peter E., Chen Zhao, Wendy Fang, et al.. (2010). The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma. Investigational New Drugs. 30(1). 191–199. 37 indexed citations

11.

Zage, Peter E., Shana L. Palla, Wendy Fang, et al.. (2010). A novel therapeutic combination for neuroblastoma. Cancer. 116(10). 2465–2475. 24 indexed citations

12.

Konopleva, Marina, Juliana Benito, Yuexi Shi, et al.. (2009). Therapeutic Targeting of the Hypoxic Microenvironment in Acute Lymphocytic Leukemia.. Blood. 114(22). 2040–2040. 4 indexed citations

13.

Fang, Wendy, Riitta Nolo, Sankaranarayanan Kannan, et al.. (2008). Targeting TRKA: Preclinical Evaluation of AZ23 in Acute Myeloid Leukemia. Pediatric Blood & Cancer. 52(6).

14.

Fang, Wendy, Sankaranarayanan Kannan, Riitta Nolo, et al.. (2008). Understanding the Role of TRKA Receptor in Acute Myeloid Leukemias: From Proliferation and Pro-Survival Signals to a Novel Therapeutic Approach. Blood. 112(11). 3789–3789. 1 indexed citations

15.

Xing, Dongxia, Wendy Fang, William K. Decker, et al.. (2007). Ex Vivo Expansion of Cord Blood NK Cell Have In Vivo Efficacy Against Leukemia.. Blood. 110(11). 2741–2741. 2 indexed citations

16.

Sutphin, Robert M., Wendy Fang, Claudia P. Miller, & Patrick A. Zweidler‐McKay. (2006). Notch Agonists: Emerging as a Feasible Therapeutic Approach in AML.. Blood. 108(11). 1419–1419. 2 indexed citations

17.

Wellstein, Anton, Wendy Fang, Aparajita Khatri, et al.. (1992). A heparin-binding growth factor secreted from breast cancer cells homologous to a developmentally regulated cytokine.. Journal of Biological Chemistry. 267(4). 2582–2587. 112 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact